TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021
TRACON Pharmaceuticals (NASDAQ:TCON) announced it will report its third quarter 2021 financial and operating results on November 3, 2021, after U.S. markets close. A conference call will follow at 4:30 PM ET to update on corporate activities and financial results. The company specializes in developing targeted therapies for cancer using a cost-efficient, CRO-independent platform. Its clinical pipeline includes Envafolimab for sarcoma, YH001 and TRC102 for various cancers, and TJ004309 for solid tumors. For more details, visit their website.
- TRACON develops targeted cancer therapies, potentially increasing market interest.
- The company is actively pursuing corporate partnerships for U.S. commercialization.
- None.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, November 3, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
| Conference call and webcast: | |
| Date: | November 3, 2021 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 4846079 |
| Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Brian Ritchie |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | (212) 915-2578 |
| mwiggins@traconpharma.com | britchie@lifesciadvisors.com |
FAQ
When will TRACON Pharmaceuticals report its third quarter 2021 financial results?
What time is the TRACON Pharmaceuticals conference call on November 3, 2021?
What is the focus of TRACON Pharmaceuticals' clinical pipeline?
How can I access the TRACON Pharmaceuticals conference call?
